Media Advisory: Dr. Jennifer Holmgren to Receive BIO Award Honoring an Outstanding Woman in Industrial Biotechnology

Dr. Jennifer Holmgren, Chief Executive Officer of the innovative carbon recycling company LanzaTech, will deliver remarks and will be presented the inaugural Rosalind Franklin Award by BIO at the 2015 World Congress on Industrial Biotechnology in Montréal.

BIO Applauds Committee Passage of Safe and Accurate Food Labeling Act

BIO applauds bipartisan action today by the U.S. House Agriculture Committee to advance the Safe and Accurate Food Labeling Act (H.R. 1599).

Media Advisory: Solazyme CEO Jonathan S. Wolfson to Receive the 2015 George Washington Carver Award

The George Washington Carver Award Will Be Presented at the 12th Annual BIO World Congress on Industrial Biotechnology; Winner to Provide Remarks

The 20TH Presidential Green Chemistry Challenge Awards Industrial Biotechnology Companies for Innovative Efforts to Tackle Climate Change and Pollution Prevention

Biotechnology companies LanzaTech and Renmatix today received awards in the Presidential Green Chemistry Challenge for industrial biotechnology applications that produce carbon negative renewable chemicals and fuels. BIO congratulates its member companies on receiving the awards, which recognize industrial biotechnology’s contribution to reducing pollution at the source.

BIO Submits Comments on Nonclinical Assessment of Investigation Enzyme Replacement Therapies

The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment.”

BIO Submits Comments on FDA on Biosimilars Q&A Draft Guidance

The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (May 2015)” (“Q&A Draft Guidance”).

BIO Praises House of Representatives for 21st Century Cures Legislation Passage

We praise the House of Representatives for today’s vote to pass 21st Century Cures legislation that recognizes the critical link between research, development and reimbursement to expedite the delivery of breakthrough treatments and cures to patients suffering from life-threatening and debilitating diseases.  

U.S. Farmers Choose to Plant Biotech Crop Varieties, Report Shows

American farmers continue to value the economic, environmental and societal benefits of genetically engineered (GE) crops – especially GE soybeans, cotton and corn – according to newly released data from the U.S. Department of Agriculture (USDA).

BIO Letter of Support for 21st Century Cures Legislation

We applaud Chairman Fred Upton (R-MI), Ranking Member Frank Pallone (D-NJ) and Congresswoman Diana DeGette’s (D-CO) efforts on H.R. 6., which takes important steps toward placing patients at the center of the drug development process, and we believe will help spur the development of therapies for the most prevalent conditions, as well as encourage development of treatments focused on rare conditions and other unmet medical needs. We strongly support establishing a framework for incorporating patient views into the development and regulatory review processes in a more structured and transparent way, both with respect to patient input for benefit-risk assessments and use of patient experience data in regulatory decision-making.

BIO Opposes Brat Amendment to Make Mandatory NIH Funding Discretionary

BIO issued the following statement regarding an amendment to the 21st Century Cures Initiative legislation filed by Rep. Dave Brat (R-VA) that would convert the mandatory funding for the National Institutes of Health (NIH) to discretionary spending.